Allogeneic hematopoietic stem cell transplantation (HSCT) with the conventional cyclophosphamide and total body irradiation (CY/TBI) regimen is an essential therapeutic strategy for acute lymphoblastic leukemia (ALL) in adults. Medium-dose etoposide (VP16, 30-40 mg/kg) can be added to intensify this CY/TBI regimen and reduce relapse; however, differences in prognosis between the VP16/CY/TBI and CY/TBI regimens have not yet been fully analyzed. We conducted a retrospective cohort study using a Japanese transplant registry database to compare the progno- (HR, 0.88; 95%CI, P 5 .38). This study is the first to reveal the efficacy of the addition of medium-dose VP16 to CY/TBI in high-risk ALL. To establish new myeloablative conditioning regimens including VP16, a large-scale prospective study is necessary. 
| I N TR ODU C TI ON
For patients with acute lymphoblastic leukemia (ALL), allogeneic hematopoietic stem cell transplantation (HSCT) is an effective therapeutic option. [1] [2] [3] Various conditioning regimens have been adopted in HSCT since its emergence in the clinical field. Cyclophosphamide with total body irradiation (CY/TBI) regimen and intravenous busulfan with CY (BU/CY) regimen are the conventional myeloablative regimens. 1 In addition, an intensified regimen offering stronger anti-leukemic effects without increased adverse effects has been proposed in ALL to reduce post-transplant relapse, particularly in patients at high risk of posttransplant relapse. 4 Among these regimens, the addition of mediumdose etoposide (VP16, 30-40 mg/kg) to the conventional CY/TBI regimen may be a promising strategy. In previous smaller studies in Japan, the VP16/CY/TBI regimen was reportedly associated with a low incidence of relapse and a fair outcome. [5] [6] [7] However, most of these studies were single arm, and the outcomes were not compared with those of standard regimens such as CY/TBI. Moreover, the subgroups in which the addition of VP16 is most beneficial remain undetermined.
Higher incidences of infection or organ dysfunction resulting in nonrelapse mortality (NRM) may be possible in conditioning regimens including VP16. 8 Therefore, we performed a cohort study using the Japanese transplant registry database of ALL to compare the prognosis and the clinical course in patients who underwent HSCT after the VP16/CY/TBI regimen with those in patients who received the CY/TBI regimen, with respect to leukemia-free survival (LFS) as the primary endpoint, and relapse, NRM, overall survival (OS) and transplant-related adverse effects such as engraftment failure, infection, and graft-versus-host disease (GVHD) as the secondary endpoints. We expected our results could provide significant evidence in favor of or against the addition of VP16 to CY/TBI for ALL.
| M E TH ODS

| Inclusion and exclusion criteria
Data on adult patients (age 16 years) with ALL who underwent allo- were selected at the discretion of the attending physicians, including the dosage of VP16. Grafts were transplanted without T-cell depletion.
Our protocol complied with the Declaration of Helsinki, and it was approved by the Ethics Committee of Kyoto University, where the study was performed. Patient information is anonymized, and the patients consented to provide the data to the data center.
| Data collection and definition of each covariate
From the registry database, we extracted data on pretransplant charac- 12 Patients were categorized into two groups with respect to age (younger vs. older than the median).
With respect to post-transplant clinical courses, engraftment of neutrophils and platelets was defined as the first day of three consecutive days during which neutrophil and platelet counts were at least 500/lL and 20 3 10 9 /L, respectively, without transfusion support.
Diagnosis and classification of acute GVHD (aGVHD) were performed by the attending physicians at each center based on conventional criteria. 13, 14 Chronic GVHD (cGVHD) was diagnosed according to the conventional criteria, and classified as limited or extensive cGVHD. 15 The cumulative incidence of infection with bacteria (determined by culture), fungi (such as Candida and Aspergillus spp., determined by serological test), or viruses (such as cytomegalovirus and Epstein-Barr virus determined by PCR test) was compared between the CY/TBI and the VP16/ CY/TBI groups; these clinical tests were performed periodically or at the onset of symptoms according to the guideline of the Japanese Society for Hematopoietic Cell Transplantation. 16 A protective environment, prophylactic administration of antibiotics (usually fluoroquinolone, fluconazole, and acyclovir), and intravenous immunoglobulin replacement for hypogammaglobulinemia were adopted as standard preventive strategies for infection in accordance with the guideline. 16 The incidence of common acute phase post-transplant complications such as thrombotic microangiopathy (TMA), interstitial pneumonitis, acute respiratory distress syndrome, hemorrhagic cystitis, veno-occlusive disease, lymphoproliferative disorder, and secondary malignancy was included in the dataset. The data on adverse events, along with those on infections,
were first reported to the data center on Day100 after HSCT and annually thereafter.
| Statistical analyses
Statistical analyses were performed as previously described. 4, 17 Table S1 ). The median follow-up period for survivors was 46.5 months (range, 2.6-168.6 months) after HSCT. Variables related to pretransplant patient characteristics are shown in Table 1; the patient age, disease status (CR1, CR2, and CR3 or later), ALL phenotype, GVHD prophylaxis, and HSCT year showed significantly different distributions between the two regimens, while performance status and disease risk did not show significant differences. The median dose of TBI was 12 Gy in both groups, and there were no significant differences. Data on pretransplant induction and consolidation regimens were not included in this database.
| Improved LFS and reduced relapse without increased NRM in the VP16/CY/TBI group
The LFS of the VP16/CY/TBI group was superior to that of the CY/TBI group ( Figure 1A ; 76.0% vs. 71.5% at 1 year; and 65.5% vs. 59.6% at 3 years after HSCT). This difference was significant in the univariate analysis ( We also performed propensity score matching analysis to maximally eliminate the differences in pretransplant characteristics between the two groups; the propensity score in the choice of conditioning regi- Figure S1 .
Comparison of OS is shown in Supporting Information
In the total cohort, prognosis with VP16/CY/TBI was superior to that with CY/TBI with borderline significance (Supporting Information Figure S1A ; adjusted HR, 0.80; 95%CI, 0.64-1.01; P 5 .06). In patients at CR1, VP16/CY/TBI was associated with better OS only in the advanced risk group, although the association was not significant (Supporting Information Figure S1B ; HR, 0.86; 95%CI, 0.63-1.17; P 5 .34).
On the contrary, addition of VP16 was associated with improved OS in all patients at CR2, regardless of the risk (Supporting Information Figure   S1C ; standard risk; HR, 0.49; 95%CI, 0.18-1.29; P 5 .15; and advanced risk; HR 0.69; 95%CI, 0.40-1.17; P 5 .17).
Differences in the NRM and relapse were analyzed in the same manner. VP16/CY/TBI was not found to induce any significant increase in NRM in the total patient cohort ( Figure 1B and In contrast, relapse was significantly reduced in the VP16/CY/TBI group in the analysis of the total cohort ( Figure 1C and Table 2 ; relative Figure S4 ).
NRM and relapse were also analyzed in the same subgroups (standard-or advanced-risk in CR1 Figure S4 ).
Relapse significantly decreased in advanced-risk patients (RR, 0.68; 95%CI, 0.46-0.99; P 5 .04) but not in standard-risk patients (RR, 0.81; 95%CI, 0.39-1.66; P 5 .57) (Supporting Information Figure S4 ).
| Improved LFS was observed irrespective of disease risk in HSCT at CR2 or later status
Effects of VP16 on LFS were analyzed in patients transplanted at CR2 or later remission status to determine whether a prognostic difference also exists according to disease risk in these patients. Subgroup analyses suggested improvement in LFS with significance or borderline significance in both standard-and advanced-risk patients (HR, 0.39; Figure S5 ). The incidence of relapse displayed a tendency to decrease in the VP16-containing regimen, although the difference was without significance mainly due to the small number of patients (RR, 0.51; 95%CI, 0.20-1.33; P 5 .17 in the standard-risk subgroup, and RR, 0.72; 95%CI, 0.35-1.44; P 5 .35 in the advanced-risk subgroup) (Supporting Information Figure S5 ). Here, the incidence of relapse in standard risk is indicated as higher than that in advanced risk, mainly due to the much higher incidence of NRM in the latter group.
| Influence of VP16 on post-transplant clinical courses
To address the differences that additional VP16 can induce in clinical courses, we focused on acute and chronic GVHD, engraftment, and several common complications after HSCT in each of the conditioning regimen groups (Figure 2 and Supporting Information Table S2 ). Table S2 ). The incidence of secondary malignancy did not increase despite VP16-containing regimen usage (1.2% for CY/TBI vs. 0.5% for VP16/CY/TBI) (Supporting Information Table S2 ).
We also compared the causes of NRM between the CY/TBI and VP16/CY/TBI regimens (Supporting Information Table S3 ); the major causes of NRM were infection, GVHD, and organ failures in both groups, and there were no significant differences in the distribution of causes of death between the two regimens.
| D ISC USSION
The present retrospective cohort study investigating the addition of Table 1 .
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First, we clearly demonstrated that addition of VP16 to CY/TBI yielded a beneficial effect on LFS in high-risk patients (i.e., patients at CR1 with advanced-risk including those with positive MRD, poor-risk karyotypes, or higher tumor burden at diagnosis, and patients at CR2
or later with any risk). This effect was attributed to the suppressed relapse after HSCT. Our comparisons were the first performed in a large-scale database analysis. Previous studies by Shigematsu et al. [5] [6] [7] suggested a fair prognosis in patients treated with VP16/CY/TBI, but these were single-arm or small-scale studies, and comparison with control arms has not been fully reported.
The therapeutic advantage of the VP16/CY/TBI regimen compared with that of the CY/TBI regimen may derive in part from to the strong anti-leukemia effects of VP16. In addition, combination regimens including VP16 are reportedly effective for leukemia cells with both myeloid 22 and lymphoid 23 lineages. VP16 exerts strong effects on leukemia cells through the upregulation of apoptotic cytokines such as interleukin-8. 24 Moreover, VP16 delivers synergistic cytocidal effects in combination with 4-hydroperoxycyclophosphamide, which is an analog of CY. 25 These pharmacokinetic and pharmacodynamic features of VP16 could provide support for our findings of reduced relapse and improved prognosis.
However, it should be noted that this prognostic advantage was not apparent in the low-risk subgroup, that is, patients at CR1 with standard risk (MRD negative, normal or low-risk karyotypes, and lack of remarkable elevation of leukocytes at diagnosis). Up to 20% of patients in this subgroup experienced post-transplant relapse, and these data emphasize the importance of identifying other strategies to reduce relapse and improve LFS in this subgroup of patients; additional novel strategies such as molecular targeting therapies 26, 27 or immunotherapies 28 events, data on mucositis were not available in our dataset, although VP16-containing regimens are known to be associated with higher risk of severe mucositis, especially in cases of high-dose VP16
(120 mg/kg) 29 ; as for medium-dose VP16, however, the previous report did not show any increased incidence of severe mucositis.
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VP16 has reportedly led to increased NRM when used in conditioning regimens. [30] [31] [32] In these reports, the dosage was 60 mg/kg or more, which was higher than that used in the patients in our study ("medium" dose of VP16; total 30-40 mg/kg). The medium dose (30-40 mg/kg) instead of the high dose (60 mg/kg or more) could be essential to decrease relapse without increasing adverse events after HSCT. 33 Our data indicated that any complications in the medium-dose VP16/CY/ TBI regimen (including a slightly higher incidence of aGVHD) could be controlled, and that VP16 did not induce additional fatal posttransplant complications in the patients treated with this regimen.
Subgroup analyses of NRM examining patient age also supported the rationale for the addition of VP16. Herein, NRM was strongly associated with patient age, as in other reports, 34, 35 have existed. We carefully dealt with these confounding factors and selection bias using multivariate analyses, subgroup analyses, and propensity score matching, but their influence cannot completely be discounted.
A lower incidence of NRM may possibly be related to the characteristics of the Japanese people; a more genetically homogeneous population may experience a lower incidence of GVHD and related adverse events, 36 indicating that there is possibility that our results cannot be directly applied to cohorts in the United States and Europe.
The exclusion of UR-PBSCT in our cohort may bias the results toward reduced total NRM, because UR-PBSCT is related to higher incidence of severe GVHD and NRM. 37 Sufficient attention should be paid to patient age. The present study included only patients transplanted with myeloablative conditioning regimens, and the median patient age was as young as 35 years. Therefore, the benefit of additional VP16 may not apply to the cohort composed of older patients, although our results showed that the difference in NRM between the CY/TBI and VP16/CY/TBI regimens was within the negligible range irrespective of patient age.
The average age of patients undergoing transplants is currently increasing, 38,39 so future analyses focusing on older patients will be necessary.
Finally, treatment center effects were not considered in our analysis; information on the HSCT centers where each patient underwent transplantation was not available from the study database. Therefore, prospective randomized controlled trials are still essential to overcome these limitations.
In conclusion, we found that the VP16/CY/TBI regimen was superior to the conventional CY/TBI regimen in myeloablative HSCT for adult ALL with higher risk (CR1 with advanced-risk and CR2 or later with any risk stratification). A lower incidence of relapse without increasing NRM resulted in better LFS. Adverse effects owing to VP16
can be appropriately managed and tolerated in each patient age group.
Therefore, addition of VP16 may be beneficial in high-risk ALL. This regimen should be compared not only with CY/TBI but also with other newly developed myeloablative regimens including busulfan, treosulflan, thiotepa, etoposide, or fludarabine in prospective studies including patients of various ethnicities. These studies will be helpful to establish new myeloablative conditioning regimens including the administration of VP16, as well as to improve the overall prognosis of ALL.
